AIMM’s focus is to interrogate the B-cell antibody response of cancer survivors to identify novel and innovative treatments for yet unserved or underserved cancer patients.
Utilizing our AIMSelect and AIMProve platforms, AIMM has developed a strong pipeline of novel drug candidates that bind new and unexpected targets and epitopes. Our ability to identify functional antibodies and their novel targets is facilitated by a well optimized process that includes target identification and confirmation as well as an understanding of fundamental immunology.
Our lead asset is AT1412 (see illustration below), an antibody that binds to a unique epitope on CD9. AT1412 allows CD9 tumor targeting without the induction of platelet aggregation. AIMM is advancing the CD9 lead program through preclinical development, with the goal of filing a Clinical Trial Application in Q4 2020 and treating the first patients in early 2021.